| Literature DB >> 28785668 |
Isac C Thomas1, David P Cork1, Ankit K Bhatia1, Hemal M Nayak1, Martin C Burke1, Joshua D Moss1.
Abstract
BACKGROUND: In patients with heart disease, the presence of a fragmented QRS complex (fQRS) on the surface electrocardiogram (ECG) is associated with an increased risk of mortality. We sought to evaluate the prevalence and location of fQRS before and after left ventricular assist device (LVAD) implantation and any associated risk of mortality. METHODS ANDEntities:
Keywords: ECG; Fragmented QRS; Left ventricular assist device; Mortality; Survival
Year: 2014 PMID: 28785668 PMCID: PMC5497182 DOI: 10.1016/j.ijcha.2014.10.017
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Fig. 1a: Pre-LVAD twelve-lead ECG showing fragmented QRS (fQRS) in leads II, III and aVF (inferior territory).
b: Post-LVAD twelve-lead ECG in same patient showing new fragmented QRS (fQRS) in leads V2 and V3 (anterior territory).
Baseline patient characteristics (n = 98).
| Age (years) | 57 ± 13 |
| Male (%) | 73 |
| Female (%) | 27 |
| Ischemic cardiomyopathy (%) | 49 |
| Non-ischemic (%) | 51 |
| Pre-LVAD LVEF (%) | 18 ± 6 |
| HeartMate II LVAD (%) | 83 |
| HeartWare HVAD (%) | 17 |
| Beta blocker use (%) | 30 |
| Amiodarone use (%) | 48 |
| Other antiarrhythmic use (%) | 16 |
| Narrow QRS complex (%) | 35 |
| Wide QRS complex (%) | 65 |
| Ventricularly paced (%) | 53 |
LVEF = left ventricular ejection fraction.
Values presented as mean ± standard deviation.
Thoratec, Pleasanton, CA.
HeartWare International, Miramar, FL.
During hospitalization post-LVAD implant or on discharge.
Lidocaine or mexiletine.
Prevalence and distribution of fragmented QRS by territory before and after LVAD implantation.
| Pre-LVAD ECG (n = 98) | Early post-LVAD ECG (≤ 7 days) (n = 96) | p | Delayed post-LVAD ECG (≥ 30 days) (n = 85) | p | p | |
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||||
| fQRS (any territory) | 28 (29) | 46 (48) | < 0.001 | 33 (39) | 0.15 | 0.57 |
| Anterior (V1–V5) | 10 (10) | 31 (32) | < 0.001 | 22 (26) | < 0.01 | 0.73 |
| Inferior (II, III, aVF) | 19 (19) | 23 (24) | 0.45 | 21 (25) | 0.80 | 1.00 |
| Lateral (I, aVL, V6) | 12 (12) | 15 (16) | 0.34 | 9 (11) | 1.00 | 0.51 |
Comparison of Pre-LVAD to Post-LVAD.
Comparison of Pre-LVAD to Delayed-post LVAD.
Comparison of Post-LVAD to Delayed-post LVAD.
Clinical characteristics of patients with and without fragmented QRS following LVAD implantation.a
| Early post-LVAD ECG (≤ 7 days) (n = 96) | Late post-LVAD ECG (≥ 30 days) (n = 85) | |||
|---|---|---|---|---|
| fQRS + (n = 46) | fQRS − (n = 50) | fQRS + (n = 33) | fQRS − (n = 52) | |
| Age (years) | 56 ± 14 | 57 ± 12 | 55 ± 15 | 56 ± 14 |
| Ischemic cardiomyopathy (%) | 56 | 41 | 56 | 37 |
| Male (%) | 74 | 76 | 79 | 71 |
| LVEF (%) | 16 ± 7 | 18 ± 7 | 17 ± 8 | 17 ± 7 |
| HeartMate II (%) | 83 | 84 | 76 | 89 |
| HeartWare (%) | 17 | 16 | 24 | 11 |
LVEF = left ventricular ejection fraction; HeartMate II, Thoratec, Pleasanton, CA; HeartWare HVAD, HeartWare International, Miramar, FL.
Differences in clinical characteristics not statistically significant (p > 0.05).
Survival outcomes over 30 months in patients with continuous-flow LVAD.
| Patients included in survival analysis | Patients with available late post-LVAD ECG (≥ 30 days) | p | ||
|---|---|---|---|---|
| (n = 98) | Fragmented V1–V5 (n = 23) | Non-fragmented V1–V5 (n = 62) | ||
| Alive/transplanted | 43% | 26% | 55% | 0.03 |
| Expired | 57% | 74% | 45% | |
| Sepsis | 13% | 13% | 11% | NS |
| ICH/stroke | 10% | 17% | 5% | 0.08 |
| Hemorrhage | 3% | 4% | 2% | NS |
| LVAD complication | 6% | 13% | 3% | 0.12 |
| VA | 1% | 0% | 0% | NS |
| RHF | 1% | 0% | 2% | NS |
| Other | 4% | 4% | 5% | NS |
| Unknown | 18% | 22% | 18% | NS |
ICH = intracranial hemorrhage; RHF = right heart failure; VA = ventricular arrhythmia.
2-Tailed p-value by Fisher exact test for differences between fragmented and non-fragmented V1–V5.
Based on combined survival and survival to transplant outcome in Kaplan–Meier estimate.
Includes cancer, ARDS, amiodarone toxicity, elective withdrawal of care.
Fig. 2Kaplan–Meier survival estimate for patients with and without QRS fragmentation in the anterior territory (fV1–V5) over 30 months. Patients with fV1–V5 had a significantly decreased rate of survival or survival to cardiac transplantation (p < 0.01).
Fig. 3Kaplan–Meier survival estimate for patients with and without QRS fragmentation in any territory (fQRS) over 30 months. Patients with fQRS in any territory on late post-operative ECG did not have a significantly different rate of survival or survival to cardiac transplantation compared to patients without fQRS (p = 0.33).
QRS complex characteristics and median survival (months) in patients with continuous-flow LVAD.
| Pre-LVAD | Early post-LVAD | Late post-LVAD | |
|---|---|---|---|
| QRS < 120 ms | 10.5 [4–30] | 21 [4–30] | 25 [6–30] |
| QRS ≥ 120 ms | 30 [3.5–30] | 30 [3.5–30] | 30 [15–30] |
| p | 0.093 | 0.192 | 0.183 |
| QRS morphologies | |||
| LBBB | 30 [24–30] | 24 [21–27] | 24 [13–27] |
| RBBB | 27 [21–28.5] | 22.5 [17–28] | 30 [22.5–30] |
| IVCD | 30 [22.5–30] | 30 [28.5–30] | 30 [22.5–30] |
| V-paced | 27 [2.5–30] | 28.5 [2.5–30] | 30 [12–30] |
| p | 0.850 | 0.796 | 0.982 |
Values presented as median [interquartile range]. LBBB = left bundle branch block, RBBB = right bundle branch block, IVCD = non-specific intraventricular conduction delay, V-paced = ventricularly paced.